ICON plc

ICON is an Irish-headquartered developer of drugs to the pharmaceutical, biotechnology and medical device industries. ICON offers consulting, clinical development and commercialisation services in a broad range of therapeutic areas from a global network of offices. As of September 2020, ICON had 15,250 employees in 94 locations spread across 40 countries.[1]

See also: Icon (disambiguation)
ICON plc
TypePublic
NASDAQ: ICLR
Industry
Founded1990 (1990) in Dublin, Ireland
FoundersJohn Climax, Co-founder, Ronan Lambe, Co-founder
Key people
Steve Cutler, CEO
ProductsServices for pharmaceutical, biotech and medical device industries
Revenue$2,595.8 million
Number of employees
14,600
Websitehttps://www.iconplc.com

History

ICON was founded in Dublin, Ireland, by John Climax, Ph.D., and Ronan Lambe, Ph.D., in 1990.[2] Since January 2010, Climax has held a position on the board of directors. Lambe retired from the board of directors in 2018.

Between 1991 and 1996, ICON opened offices in the United Kingdom, United States, and Japan.[3] A year later, ICON began trading on the Nasdaq exchange.[4]

In 2018, ICON won the PharmaTimes Clinical Researcher of the Year.[5] ICON received 2019 Clinical Research Organization leadership awards in five categories,[6] determined by Life Science Leader magazine and Industry Standard Research (ISR).

Steve Cutler, PhD, was appointed Chief Executive Officer of ICON in March 2017, and previously served as Chief Operating Officer.[7]

Acquisitions
  • 2000: ICON acquired UK-based regulatory consultancy, YRCR Ltd.; Central Laboratory in New York; and bioanalytical consultancy, Pacific Research[8][9][10]
  • 2002: ICON acquired clinical research provider, BPA.[11]
  • 2003: ICON acquired Medeval, a UK-based Phase I facility, and US consulting firm, Globomax [12][13]
  • 2004: ICON acquired medical imaging specialist, Beacon Bioscience Inc.[14]
  • 2006: ICON acquired outcomes research and health economics specialist, Ovation Research Group[15]
  • 2007: ICON acquired European staffing group, DOCS International[16]
  • 2008: ICON acquired US phase I provider, Healthcare Discoveries and US bioanalytical lab, Prevalere Life Sciences[17][18]
  • 2009: ICON acquired Veeda Laboratories, a UK biomarker lab[19]
  • 2010: ICON acquired Timaq Medical Imaging Inc.[20]
  • 2011: ICON acquired Oxford Outcomes, an international health outcomes consultancy and Firecrest Clinical, a technology provider specialising in site performance and study management[21][22]
  • 2012: ICON acquired PriceSpective, a global value strategy consultancy and Chinese CRO, BeijingWits[23][24]
  • 2013: ICON acquired staffing and FSP providers, ClinForce and Assent and Akos, an EU provider of pharmacovigilance and drug safety services[25][26]
  • 2014: ICON acquired Aptiv Solutions, a market leader in adaptive trial design and execution[27]
  • 2015: ICON acquired MediMedia Pharma Solutions to enhance market access and scientific communications capabilities, and PMG Research Inc., an integrated network of clinical research sites in the US[28][29]
  • 2016: ICON acquired Clinical Research Management Inc., to extend its presence in the government-sponsored research market[30]
  • 2017: ICON acquired MAPI Group, thereby becoming the world’s second-largest provider of late-phase services[31]
  • 2019: ICON acquired Symphony Clinical Research, a leading provider of at-home patient services and site-support services; MediNova, an integrated network of clinical research sites across EMEA; and MolecularMD, to enhance its laboratory offerings in molecular diagnostic testing and immunohistochemistry[32][33][34]

Therapeutic Areas

ICON has a broad range of therapeutic areas which include, but are not limited to Oncology, Vaccines, CNS, Cardiovascular and CNS.[35]

Activities

Drug and device development

ICON assists pharmaceutical, biotechnology and medical device companies with drug and device development services covering entire lifecycle of product development, ranging from small local clinical trials to large global programs.

Adaptive trials

ICON designs, simulates and executes adaptive clinical trials. ICON states it is the only CRO to offer a validated design, simulation and analysis software platform for adaptive clinical trials. This platform is used by regulatory agencies around the world including the FDA, EMA, and PMDA.[36][37]

Clinical Research Services

ICON specialises in the planning, management, execution, and analysis of Phase II - III clinical trials. ICON’s services within this area include project management, clinical operations/monitoring, patient centric monitoring and data management.[38]

Commercialisation

ICON’s commercialisation and outcomes function includes real world evidence strategy and analytics; late-phase patient and site engagement, and language services; strategic regulatory services; and medical device & diagnostics research. Also, ICON is a sponsor of Mapi Research Trust, a non-profit organisation dedicated to improving patients’ quality of life by facilitating access to patient-centered outcome information.[39][40][41]

Early phase studies

ICON supports services such as patient studies, clinical research unit, pharmacodynamic models, data visualisation, NONMEM software, PK/PD Pop software, and precision methodology cardiac assessment.[42]

Functional Services Provision (FSP) and Strategic Resourcing

ICON provides global FSP partnerships and strategic resourcing for a range of functions including clinical data management, pharmacovigilance, biostatistics, drug safety, medical writing and for roles such as clinical research associate and clinical trial associate. The company also provides strategic capacity management, program insourcing, and contingent resourcing.[43]

Medical Imaging

ICON incorporates medical imaging as part of their clinical trial support, including assessing clinical trial endpoints for Phase I - IV trials, imaging for efficacy and safety, support for early phase decision-making, and statistical support for validation of novel scales and methods.[44]

Laboratories

ICON provides laboratory services dedicated to clinical development including analytical testing services, central laboratory testing and integrated clinical research.[45]

See also

References
  1. "Q3 2020 Results". ICON PLC. Retrieved 25 November 2020.
  2. "Icon founders poised to make $45m in share placing". Irish Times. 24 July 2003. Retrieved 8 December 2019.
  3. Langan, Sheila (1 October 2014). "ICON of Ireland". Irish America. Retrieved 8 December 2019.
  4. "ICON plc : ICON Announces the Commencement of Direct Trading on NASDAQ". Market Screener. 5 February 2013. Retrieved 8 December 2019.
  5. "Winner 2018". Pharma Times. December 2018. Retrieved 8 December 2019.
  6. "ICON Wins Multiple Categories in 2019 CRO Leadership Awards". BusinessWire. 5 March 2019. Retrieved 8 December 2019.
  7. "BRIEF-ICON says Steve Cutler to be named CEO". Reuters. 20 October 2016. Retrieved 8 December 2019.
  8. "YRCR was acquired by ICON on February 3, 2000". Mergr. Retrieved 8 December 2019.
  9. Barrington, Kathleen (10 June 2000). "Icon buys UCT for $2m cash plus $18m deferred payments". Independent. Retrieved 8 December 2019.
  10. McGrath, Brendan (1 February 2000). "Icon buys US data group in first public acquisition". The Irish Times. Retrieved 8 December 2019.
  11. "Form 20-F". Securities and Exchange Commission. United States Government. Retrieved 8 December 2019.
  12. "Form 20-F". Securities and Exchange Commission. United States Government. Retrieved 8 December 2019.
  13. "ICON Acquires GloboMax". Mergr. Retrieved 8 December 2019.
  14. "Beacon Bioscience Acquired by ICON July 1, 2004". Crosstree Capital. Retrieved 8 December 2019.
  15. "ICON Acquires Ovation Research Group". Mergr. Retrieved 8 December 2019.
  16. Mansell, Peter (16 July 2007). "ICON acquires clinical research staffer DOCS International". Pharma Times. Retrieved 8 December 2019.
  17. "ICON Acquires Healthcare Discoveries". Contract Pharma. 12 February 2008. Retrieved 8 December 2019.
  18. MacDonald, Gareth (22 October 2009). "Icon boosts bioanalytical presence through Prevalere buy". Outsourcing Pharma. Retrieved 8 December 2019.
  19. "ICON Acquires Veeda Laboratories Ltd". Biospace. 8 December 2008. Retrieved 8 December 2019.
  20. Rhea, Shawn (24 May 2010). "Icon acquires Timaq Medical Imaging". Modern Healthcare. Retrieved 10 December 2019.
  21. Mansell, Peter (18 January 2011). "ICON broadens late-phase expertise with Oxford Outcomes acquisition". PharmaTimes. Retrieved 10 December 2019.
  22. Lynch, Suzanne (15 July 2011). "Pharmaceutical firm Icon buys Firecrest Clinical for undisclosed sum". The Irish Times. Retrieved 10 December 2019.
  23. "ICON-PLC Acquires PriceSpective". Biospace. 28 February 2012. Retrieved 10 December 2019.
  24. "ICON Acquires BeijingWits Medical Consulting Ltd". BioSpace. 12 December 2011. Retrieved 10 December 2019.
  25. "DOCS Acquires ClinForce and Assent Consulting". DOCS Global. DOCS. Retrieved 10 December 2019.
  26. Mansell, Peter (5 February 2013). "Icon to acquire Cross Country's Clinical Trial Services Division". PharmaTimes. Retrieved 10 December 2019.
  27. Mansell, Peter (1 April 2014). "ICON to acquire Aptiv Solutions for US$143.5 million". PharmaTimes. Retrieved 10 December 2019.
  28. "ICON Completes Acquisition Of MediMedia Pharma Solutions". BioSpace. 2 March 2015. Retrieved 10 December 2019.
  29. "ICON Acquires PMG Research". Contract Pharma. 7 December 2015. Retrieved 10 December 2019.
  30. "ICON Completes the Acquisition of Clinical Research Management, Inc". BusinessWire. 19 September 2016. Retrieved 10 December 2019.
  31. "ICON Acquires Mapi Group". Health Economics. Retrieved 10 December 2019.
  32. "Symphony Clinical Research Acquired by ICON". Symphony Clinical Research. Retrieved 10 December 2019.
  33. "ICON's Acquisition of MeDiNova Research". Bloomberg. Retrieved 10 December 2019.
  34. Pennic, Fred (21 February 2019). "ICON Acquires Precision Medicine for Oncology Company MolecularMD". HIT Consultant. Retrieved 10 December 2019.
  35. "ICON plc". Indeed. Retrieved 10 December 2019.
  36. Lynch, Maggie (8 October 2018). "Icon launches technology for adaptive clinical trial design". Outsourcing Pharma. Retrieved 10 December 2019.
  37. "Real World Evidence Generation: The Value Of Cross-Sectional Studies, Medical Chart Reviews And Hybrid Designs". Clinical Leader. Retrieved 10 December 2019.
  38. "ICON - Global provider of outsourced drug development and commercialisation services to pharmaceutical, biotechnology, medical device, government and public health organisations". WorldPharma. Retrieved 10 December 2019.
  39. "ICON - Global provider of outsourced drug development and commercialisation services to pharmaceutical, biotechnology, medical device, government and public health organisations". WorldPharma. Retrieved 10 December 2019.
  40. Pinching, John (1 January 2019). "Centre of the pharmaverse". PharmaTimes. Retrieved 10 December 2019.
  41. "Mapi Research Trust". Mapi Research Trust. Retrieved 10 December 2019.
  42. "ICON - Global provider of outsourced drug development and commercialisation services to pharmaceutical, biotechnology, medical device, government and public health organisations". WorldPharma. Retrieved 10 December 2019.
  43. "ICON Launches New Functional Service Provision (FSP) Strategy". Business Wire. Retrieved 10 December 2019.
  44. "ICON Medical Imaging Inc". Bloomberg. Retrieved 10 December 2019.
  45. Fassbender, Melissa (26 February 2019). "Icon nabs molecular diagnostic lab to support precision medicine programs". Outsourcing Pharma. Retrieved 10 December 2019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.